

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Brilliant Violet 421(TM) anti-mouse/human CD44

RRID:AB_2616903

Type: Antibody

Proper Citation

BioLegend Cat# 103040, RRID:AB_2616903

Antibody Information

URL: http://antibodyregistry.org/AB_2616903

Proper Citation: BioLegend Cat# 103040, RRID:AB_2616903

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-P

Antibody Name: Brilliant Violet 421(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2616903

Vendor: BioLegend

Catalog Number: 103040

Alternative Catalog Numbers: 103039

Record Creation Time: 20231110T034919+0000

Record Last Update: 20260829T195534+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4+ memory. *iScience*, 29(5), 115593.

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Li C, et al. (2025) Integrin CD103 expression in naive CD8+ T cells promotes cytokine-driven acquisition of memory phenotype and effector function. *Immunity*.

Del Rey-Vergara R, et al. (2025) MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer. *Cell reports. Medicine*, 6(7), 102194.

Daray FM, et al. (2024) Decoding the inflammatory signature of the major depressive episode: insights from peripheral immunophenotyping in active and remitted condition, a case-control study. *Translational psychiatry*, 14(1), 254.

Srivastava N, et al. (2024) CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8+ T cells in diabetic autoimmunity. *Immunity*, 57(7), 1629.

Ichiyama K, et al. (2024) Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. *Immunity*, 57(9), 2043.

Choi S, et al. (2024) Protein-energy restriction-induced lipid metabolism disruption causes stable-to-progressive disease shift in *Mycobacterium avium*-infected female mice. *EBioMedicine*, 105, 105198.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. *Immunity*, 56(1), 207.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Dean JW, et al. (2023) The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8⁺ T cell differentiation and function. *Cell reports*, 42(1), 111963.

Cao W, et al. (2023) TRIB2 safeguards naive T cell homeostasis during aging. *Cell reports*, 42(3), 112195.

Mirshahi F, et al. (2022) Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. *Cell reports*, 38(9), 110454.

Cheng AG, et al. (2022) Design, construction, and in vivo augmentation of a complex gut microbiome. *Cell*, 185(19), 3617.

Jiang W, et al. (2021) A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. *Cell reports*, 37(11), 110112.

Wu J, et al. (2020) T Cell Factor 1 Suppresses CD103⁺ Lung Tissue-Resident Memory T Cell Development. *Cell reports*, 31(1), 107484.

Andersen L, et al. (2019) The Transcription Factor MAZR/PATZ1 Regulates the Development of FOXP3⁺ Regulatory T Cells. *Cell reports*, 29(13), 4447.

Chow MT, et al. (2019) Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. *Immunity*, 50(6), 1498.

Moguche AO, et al. (2017) Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. *Cell host & microbe*, 21(6), 695.